Triphase Accelerator Announces Orphan Drug Designation In The European Union For Marizomib For Multiple Myeloma
6/23/2014 8:58:02 AM
TORONTO & SAN DIEGO--(BUSINESS WIRE)--Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, today announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has adopted a positive opinion recommending marizomib for the treatment of multiple myeloma for designation as an orphan medicinal product in the European Union (EU). Orphan drug designation provides a number of benefits, including 10 years of market exclusivity from product launch in the EU, fee reductions, and access to the central authorization procedure. Triphase also has been granted orphan drug designation for marizomib in multiple myeloma from the U.S. Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.
comments powered by